Mail

How much should Gardasil cost? Re: "How much should Gardasil cost?",1 which argues that Merck could cut the price of its HPV [human papillomavirus] vaccine by 90% and still profit. Stop complaining that publicly traded, for-profit companies charge too much for their products. They were not established to maximize the social good. If you believe they are denying treatment due to pricing, you have other options beyond haranguing them about morality: Go to a stockholders' meeting,

| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Re: "How much should Gardasil cost?",1 which argues that Merck could cut the price of its HPV [human papillomavirus] vaccine by 90% and still profit. Stop complaining that publicly traded, for-profit companies charge too much for their products. They were not established to maximize the social good. If you believe they are denying treatment due to pricing, you have other options beyond haranguing them about morality: Go to a stockholders' meeting, campaign to change patent laws, or investigate a vaccine to compete with theirs. Personally, I'm just glad to see the pharmaceutical companies actually back to working on life-saving products instead of hair-growers and erectile-dysfunction treatments.

Robert Dodge
Falmouth, ME
robertdodge@mac.cm

In considering how much profit Merck is entitled to make on its investment,1 one should also consider the US taxpayer's investment. Two researchers at the National Cancer Institute, Douglas R. Lowy and John T. Schiller, did much of the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies